Cargando…
Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model
BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870119/ https://www.ncbi.nlm.nih.gov/pubmed/36689445 http://dx.doi.org/10.1371/journal.pone.0280907 |
_version_ | 1784876905281880064 |
---|---|
author | Dinh, Truc Sophia Meid, Andreas D. Rudolf, Henrik Brueckle, Maria-Sophie González-González, Ana I. Bencheva, Veronika Gogolin, Matthias Snell, Kym I. E. Elders, Petra J. M. Thuermann, Petra A. Donner-Banzhoff, Norbert Blom, Jeanet W. van den Akker, Marjan Gerlach, Ferdinand M. Harder, Sebastian Thiem, Ulrich Glasziou, Paul P. Haefeli, Walter E. Muth, Christiane |
author_facet | Dinh, Truc Sophia Meid, Andreas D. Rudolf, Henrik Brueckle, Maria-Sophie González-González, Ana I. Bencheva, Veronika Gogolin, Matthias Snell, Kym I. E. Elders, Petra J. M. Thuermann, Petra A. Donner-Banzhoff, Norbert Blom, Jeanet W. van den Akker, Marjan Gerlach, Ferdinand M. Harder, Sebastian Thiem, Ulrich Glasziou, Paul P. Haefeli, Walter E. Muth, Christiane |
author_sort | Dinh, Truc Sophia |
collection | PubMed |
description | BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from general practice. This study compared the ability of five measures of anticholinergic burden to predict falls. To account for patients’ individual susceptibility to medications, the added predictive value of typical anticholinergic symptoms was further quantified in this context. METHODS AND FINDINGS: To predict falls, models were developed and validated based on logistic regression models created using data from two German cluster-randomized controlled trials. The outcome was defined as “≥ 1 fall” vs. “no fall” within a 6-month follow-up period. Data from the RIME study (n = 1,197) were used in model development, and from PRIMUM (n = 502) for external validation. The models were developed step-wise in order to quantify the predictive ability of anticholinergic burden measures, and anticholinergic symptoms. In the development set, 1,015 patients had complete data and 188 (18.5%) experienced ≥ 1 fall within the 6-month follow-up period. The overall predictive value of the five anticholinergic measures was limited, with neither the employed anticholinergic variable (binary / count / burden), nor dose-dependent or dose-independent measures differing significantly in their ability to predict falls. The highest c-statistic was obtained using the German Anticholinergic Burden Score (0.73), whereby the optimism-corrected c-statistic was 0.71 after interval validation using bootstrapping and 0.63 in the external validation. Previous falls and dizziness / vertigo had the strongest prognostic value in all models. CONCLUSIONS: The ability of anticholinergic burden measures to predict falls does not appear to differ significantly, and the added value they contribute to risk classification in fall-prediction models is limited. Previous falls and dizziness / vertigo contributed most to model performance. |
format | Online Article Text |
id | pubmed-9870119 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-98701192023-01-24 Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model Dinh, Truc Sophia Meid, Andreas D. Rudolf, Henrik Brueckle, Maria-Sophie González-González, Ana I. Bencheva, Veronika Gogolin, Matthias Snell, Kym I. E. Elders, Petra J. M. Thuermann, Petra A. Donner-Banzhoff, Norbert Blom, Jeanet W. van den Akker, Marjan Gerlach, Ferdinand M. Harder, Sebastian Thiem, Ulrich Glasziou, Paul P. Haefeli, Walter E. Muth, Christiane PLoS One Research Article BACKGROUND: Anticholinergic burden has been associated with adverse outcomes such as falls. To date, no gold standard measure has been identified to assess anticholinergic burden, and no conclusion has been drawn on which of the different measure algorithms best predicts falls in older patients from general practice. This study compared the ability of five measures of anticholinergic burden to predict falls. To account for patients’ individual susceptibility to medications, the added predictive value of typical anticholinergic symptoms was further quantified in this context. METHODS AND FINDINGS: To predict falls, models were developed and validated based on logistic regression models created using data from two German cluster-randomized controlled trials. The outcome was defined as “≥ 1 fall” vs. “no fall” within a 6-month follow-up period. Data from the RIME study (n = 1,197) were used in model development, and from PRIMUM (n = 502) for external validation. The models were developed step-wise in order to quantify the predictive ability of anticholinergic burden measures, and anticholinergic symptoms. In the development set, 1,015 patients had complete data and 188 (18.5%) experienced ≥ 1 fall within the 6-month follow-up period. The overall predictive value of the five anticholinergic measures was limited, with neither the employed anticholinergic variable (binary / count / burden), nor dose-dependent or dose-independent measures differing significantly in their ability to predict falls. The highest c-statistic was obtained using the German Anticholinergic Burden Score (0.73), whereby the optimism-corrected c-statistic was 0.71 after interval validation using bootstrapping and 0.63 in the external validation. Previous falls and dizziness / vertigo had the strongest prognostic value in all models. CONCLUSIONS: The ability of anticholinergic burden measures to predict falls does not appear to differ significantly, and the added value they contribute to risk classification in fall-prediction models is limited. Previous falls and dizziness / vertigo contributed most to model performance. Public Library of Science 2023-01-23 /pmc/articles/PMC9870119/ /pubmed/36689445 http://dx.doi.org/10.1371/journal.pone.0280907 Text en © 2023 Dinh et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Dinh, Truc Sophia Meid, Andreas D. Rudolf, Henrik Brueckle, Maria-Sophie González-González, Ana I. Bencheva, Veronika Gogolin, Matthias Snell, Kym I. E. Elders, Petra J. M. Thuermann, Petra A. Donner-Banzhoff, Norbert Blom, Jeanet W. van den Akker, Marjan Gerlach, Ferdinand M. Harder, Sebastian Thiem, Ulrich Glasziou, Paul P. Haefeli, Walter E. Muth, Christiane Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model |
title | Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model |
title_full | Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model |
title_fullStr | Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model |
title_full_unstemmed | Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model |
title_short | Anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: Development and validation of a prognostic model |
title_sort | anticholinergic burden measures, symptoms, and fall-associated risk in older adults with polypharmacy: development and validation of a prognostic model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870119/ https://www.ncbi.nlm.nih.gov/pubmed/36689445 http://dx.doi.org/10.1371/journal.pone.0280907 |
work_keys_str_mv | AT dinhtrucsophia anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT meidandreasd anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT rudolfhenrik anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT bruecklemariasophie anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT gonzalezgonzalezanai anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT benchevaveronika anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT gogolinmatthias anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT snellkymie anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT elderspetrajm anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT thuermannpetraa anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT donnerbanzhoffnorbert anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT blomjeanetw anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT vandenakkermarjan anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT gerlachferdinandm anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT hardersebastian anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT thiemulrich anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT glaszioupaulp anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT haefeliwaltere anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel AT muthchristiane anticholinergicburdenmeasuressymptomsandfallassociatedriskinolderadultswithpolypharmacydevelopmentandvalidationofaprognosticmodel |